Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
© Schmidt et al.; licensee BioMed Central Ltd. 2013
Received: 27 December 2012
Accepted: 5 July 2013
Published: 10 July 2013
Mechanistic biosimulation can be used in drug development to form testable hypotheses, develop predictions of efficacy before clinical trial results are available, and elucidate clinical response to therapy. However, there is a lack of tools to simultaneously (1) calibrate the prevalence of mechanistically distinct, large sets of virtual patients so their simulated responses statistically match phenotypic variability reported in published clinical trial outcomes, and (2) explore alternate hypotheses of those prevalence weightings to reflect underlying uncertainty in population biology. Here, we report the development of an algorithm, MAPEL (Mechanistic Axes Population Ensemble Linkage), which utilizes a mechanistically-based weighting method to match clinical trial statistics. MAPEL is the first algorithm for developing weighted virtual populations based on biosimulation results that enables the rapid development of an ensemble of alternate virtual population hypotheses, each validated by a composite goodness-of-fit criterion.
Virtual patient cohort mechanistic biosimulation results were successfully calibrated with an acceptable composite goodness-of-fit to clinical populations across multiple therapeutic interventions. The resulting virtual populations were employed to investigate the mechanistic underpinnings of variations in the response to rituximab. A comparison between virtual populations with a strong or weak American College of Rheumatology (ACR) score in response to rituximab suggested that interferon β (IFNβ) was an important mechanistic contributor to the disease state, a signature that has previously been identified though the underlying mechanisms remain unclear. Sensitivity analysis elucidated key anti-inflammatory properties of IFNβ that modulated the pathophysiologic state, consistent with the observed prognostic correlation of baseline type I interferon measurements with clinical response. Specifically, the effects of IFNβ on proliferation of fibroblast-like synoviocytes and interleukin-10 synthesis in macrophages each partially counteract reductions in synovial inflammation imparted by rituximab. A multianalyte biomarker panel predictive for virtual population therapeutic responses suggested population dependencies on B cell-dependent mediators as well as additional markers implicating fibroblast-like synoviocytes.
The results illustrate how the MAPEL algorithm can leverage knowledge of cellular and molecular function through biosimulation to propose clear mechanistic hypotheses for differences in clinical populations. Furthermore, MAPEL facilitates the development of multianalyte biomarkers prognostic of patient responses in silico.
KeywordsDrug development Mechanistic modeling Biosimulation Patient population Biomarker Pharmaceutical research & development Personalized medicine
Rheumatoid arthritis (RA) is a debilitating, progressive disease that affects approximately 1% of the adult population . Clinically, RA is a symmetric polyarticular disease that is characterized by swollen and tender joints, the presence of circulating factors such as elevated C-reactive protein and rheumatoid factor, and the degradation of cartilage and bone [1, 2]. In addition to potential disability, rheumatoid arthritis is also a risk factor for cardiovascular disease and mortality.
Mechanistically, joint function is degraded by infiltration of the synovial lining by cells of the innate and adaptive immune system. Many cellular players are involved in initiating and sustaining the inflammatory response, including fibroblast-like synoviocytes, lymphocytes, monocytes, and others . The paracrine feedback of pro- and anti-inflammatory mediators makes deciphering causation difficult. Early attempts to characterize RA supported several distinct causative hypotheses, which suggested that specific soluble factors, T cells, or B cells were the dominant agent. It is now accepted the etiology is complex and that many innate and adaptive immune cell types have an important mechanistic role .
Patients exhibit a spectrum of responses to clinical therapies for RA. To assist in the assessment of therapeutic efficacy, the American College of Rheumatology has defined standards that have been employed in clinical trials to evaluate the relative improvement in the clinical, inflammation-dependent manifestation of RA with therapy . Notably, only about 50% of patients with early RA achieve a mild American College of Rheumatology 20 (ACR20) response to methotrexate, a first line therapy for treatment . Some patients that do not respond well to methotrexate respond well to the combination of methotrexate and a biologic drug targeting tumor necrosis factor α (TNF). For example, about 60% of patients exhibited a mild ACR20 response and 25% a strong ACR70 response when treated with infliximab . In lieu of a single therapeutic panacea, a variety of marketed biological therapies target alternate cytokines and cellular antigens including: interleukin-6 receptor (IL6R, tocilizumab), interleukin-1 (IL-1, anakinra), cytotoxic T-lymphocyte antigen 4 (CTLA4, abatacept), and cluster of differentiation 20 (CD20, rituximab). The emergence of multiple, mechanistically distinct targets has been suggested to reflect the existence of unique states of the network underlying RA  and/or heterogeneity in the pathogenesis of the disease. Indeed, despite these additional therapeutics, there remain patients that do not respond well to treatment.
The heterogeneity in disease states presents a challenge for the effective development of new therapies by the pharmaceutical industry. Economic analysis suggests that the pharmaceutical industry tends to pursue targets in therapeutic areas where the risk of failure is high . When there is an opportunity to be first-in-class and with a clear unmet medical need, the economic reward is great due in substantial part to a lack of competition . In RA, the presence of therapies that work well in some patients, such as anti-TNF agents, increase the risk to drug development since it is not clear whether a new drug will be more effective in an underserved, identifiable portion of the population. Although meta-analysis techniques have demonstrated utility to halt the development of generally unpromising compounds early in clinical development , it is difficult to extrapolate clinical benefit for select patient populations from preclinical models. Phenotype-driven mechanistic biosimulation can be employed to develop testable hypotheses governing efficacy, evaluate therapeutic targets in silico, address alternate scenarios of efficacy, and identify predictive biomarkers .
Methods for population PK/PD modeling are relatively mature (for a discussion, refer to ). In contrast, statistical calibration of large mechanistic biosimulation results to analyze trial efficacy at the population level has been proposed , but further development and implementation of relevant methods is still needed. These approaches are potentially of tremendous benefit to virtual study population selection. For example, characterization of virtual patient (VP) diversity has previously been employed in the context of selecting clinical trial endpoints and optimizing trial design . The assignment of prevalence weights to individual VPs to statistically recreate clinical outcome distributions in a virtual population (VPop) has been previously validated in the context of type 2 diabetes . In this study, dimensionality of the patient variability space was effectively reduced by employing principal component analysis (PCA), and the prevalence weight of individual VPs was adjusted to create a VPop with optimal agreement with data from NHANES III. Studies in drug-induced liver injury (DILI) have used parameter distribution and drug response fitting approaches to guide the development of each VP in a single population, which has been called a “SimPops” approach [15, 16]. Despite the successes of methods to develop VPops, there are challenges that limit their general applicability. First, a method for creating alternate VPops that also agree with trial data is desirable. This would more directly facilitate a comparison of best and worst-case scenarios for the improvement with therapy at the population level. Second, databases such as NHANES III contain multiple measures for individual patients, including the response to meaningful perturbations such as an oral glucose tolerance test, that facilitate dimensionality reduction by PCA. Other therapeutic areas may not have a comparable resource to assist in the multivariate analysis of patients. For example, in RA, trials of new therapies often must run for six months to one year to assess therapeutic efficacy. Additionally, it is more difficult to measure the concentrations of critical mediators in the synovial tissue. Although relevant data is available in the literature, comprehensive multivariate measures for each patient in clinical trials are not.
We report here the development of a novel algorithm, MAPEL (Mechanistic Axes Population Ensemble Linkage), for developing an ensemble of statistically-calibrated VPops that enables the development and empowers the interpretation of biomarkers from biosimulation data. The algorithm has been developed specifically to utilize data embedded in the mechanistic parameters that characterize the VPs that underlie the biosimulation. We apply the algorithm to a previously validated model of a rheumatic joint [17, 18]. The ensemble of VPops thus developed agreed well with a reported baseline type I interferon cytokine signature that distinguishes patients that respond well to rituximab . We then employed the ensemble of VPops and the biosimulation platform as tools to probe the mechanistic basis of the reported biomarker in silico since these mechanisms remain unclear in the literature.
Virtual patient cohort
To facilitate the development of population-level statistics, a cohort of VPs was first developed for analysis. Cohort VPs vary from each other in their mechanistic axes coefficients, which map onto individual model parameters. In contrast to the development of a single reference VP with responses to match the mean behavior reported in clinical trials , the acceptable responses for a VP cohort are broader and span a larger range of responses observed in the clinic . When creating the cohort, mechanistic variability in pathophysiology was introduced through variation in mechanistic axes selected on the bases of sensitivity and diversity. The aim was to capture the full spectrum of observed clinical responses to multiple therapies with distinct mechanisms of action. Once a few VPs were calibrated manually, additional VPs were created using a genetic algorithm on a computing cluster. To ensure reasonable pathologic characteristics of the VPs, the literature was reviewed for reported ranges for the density of the various inflammatory cells found in the synovium and cytokine concentrations reported in the serum (Additional file 1). The observed ranges were used to evaluate the validity of VPs as they were returned by the algorithm. Clinical responses to approved therapies for patients with inadequate responses to methotrexate were tested to ensure the full range of clinical response was observed in the VP cohort. Mechanistic axes coefficients and therapeutic response results for the virtual patient cohort are provided (included in Additional file 2).
Summary of key concepts
What is it and how is it used?
Virtual Patient (VP)
Each VP has simulated clinical responses to multiple therapeutic interventions and associated pre-intervention measures, such as cell counts and synovial cytokine concentrations. 1,206 VPs were developed.
VPs are defined by where their biology lies on the mechanistic axes. The axes introduce heterogeneity into the VPs. Axes define different VPs. Fifty-one alternate mechanistic axes were selected on the bases of sensitivity and diversity.
MAPEL assigns probabilities along the axes that are used to calculate the prevalence weight of each VP. The details are discussed in the methods.
A prevalence weight is the frequency of a VP relative to other VPs. The prevalence weight is used to calculate trial statistics. For example, 1 of the 1,206 virtual patients might be assigned 1% of the total weight even though it only accounts for 0.1% of the VPs. This VP’s prevalence weight would be 0.01. Note that all VPs receive a prevalence weight, based on the axes weights, although the weights will not be equal.
Virtual Population (VPop)
A single VPop is defined by one full set of prevalence weights for the VPs, e.g. one set of 1,206 prevalence weights. When the prevalence weights are applied to the simulated trial outcomes for each VP, the resulting statistics better match trial populations.
Clinical trials used to calibrate virtual populations with MAPEL
MAPEL step 1: initialization
The mechanistic axes were split into two bins, representing the lower and upper fiftieth percentile of values from cohort VPs, to ensure equal representation in the high and low bins. During the initialization of the optimization, each bin was randomly assigned a weight. It should be noted that since the marginal probabilities along each axis sum to 1, there is only one free probability variable per mechanistic axis.
MAPEL step 2: prevalence weight calculation from axes weights
Note that the Gaussian term in formula (2) simplifies to a product of probabilities, pj in the case when ρ is zero as we would expect. The preceding formulas are derived by applying a Gaussian bivariate copula to introduce a dependence between mechanistic axis l and k, while preserving the marginal distributions (for example, ).
MAPEL step 3: response to therapy at the virtual population level
Continuous ACR-N responses were previously simulated for each VP in the cohort. Bin counts, which are natural for ACR20, 50, 70 data available in the literature from clinical trials, were employed in conjunction with the prevalence weights to assess clinical endpoints for the response to therapies.
- 2.Weighted means and standard deviations were also calculated for the VPop based on the simulated ACR-N responses for each VP. For the simulated ACR-N response sampled at time s to treatment t, the weighted mean and standard deviation were respectively calculated according to(8)
Here, xi,t,s is the response for VP i to treatment t sampled at time s and N is the number of VPs used in the calibration. The population ACR 20, 50, and 70 responses were also calculated by summing the total prevalence weight for VPs with clinical responses falling within each response bin.
MAPEL step 4: agreement with clinical trial data and objective function evaluation
Here, B is the number of ACR response bins, NT,t,s is the number of trial patients for therapy t sampled at time s, nTt,s,b is the number of patients in trial response bin b for therapy t sampled at time s, and cb is the midpoint of response bin b (e.g. 35 for ACR20-50). The trial mean and standard deviation were included in the optimization to avoid situations where a good fit for a VPop the distribution could be achieved by shifting the weights to the VPs that fell at, e.g. the upper, edge of each response bin. The comparisons to clinical data for the population mean, standard deviation, and bin distribution were made by calculating p-values with the t-test, f-test, and chi-squared test, respectively. Fisher’s method was used to calculate the composite goodness-of-fit from individual p-values for each trial statistic to be matched. The sum of logarithms of the individual p-values was used as the optimization objective. This choice for an objective function ensured the p-values for individual statistical tests converged well and was also consistent with the application of Fisher’s method for aggregating multiple p-values together for the composite goodness-of-fit. R’s Nelder-Mead optimization algorithm was employed to update the axes weights and iterate until convergence.
Additional algorithmic details
For the purpose of optimization, bin probabilities were converted using a hyperspherical transform. The transform enabled the optimization’s independent variables to vary over an infinite range and avoided edge complications during convergence. To develop alternate VPops and explore variability in optimal solutions while maintaining statistical agreement with clinical trial results, valid VPops were used as seeds for randomization of axes weights and the development of new populations. The MAPEL algorithm, employed targets, VP cohort, and script for running a test case are supplied in Additional file 2.
We performed an analysis of the pathway effects of IFNβ on the response to rituximab therapy. IFNβ effects were either applied in a “one-on” or “one-off” fashion, similar to the one-off method applied previously . After virtual patients stabilized on methotrexate therapy in the biosimulation, either one IFNβ pathway effect was locked (“off”) or only one IFNβ pathway effect was unlocked (“on”) and able to change in response to alteration in IFNβ concentrations caused by the application of rituximab. The simulated ACR-N response was measured, and the previously determined prevalence weights for the alternate populations were applied to calculate each VPop’s response.
After developing alternate VPop prevalence weight solutions, an analysis of biomarkers was conducted. Measurements of synovial mediator concentrations were made at baseline, after twelve months of simulated methotrexate treatment, and prior to the addition of the biological therapy. One mediator was selected from sets of highly correlated mediators (ρ > 0.8), retaining the mediator with the lowest average correlation with other synovial mediators. For each virtual population, the best linear regression models were identified using an exhaustive search with the LEAPS package  in R. An initial analysis of the Bayesian information criterion (BIC, a widely used model selection metric that combines the explained variance and model complexity) for a subset of VPops suggested employing a model of 27 regressors. Alternatively, an analysis of adjusted R2 for each model size found a model size of five analytes yielded an adjusted R2 of 0.75. The purpose of the analysis was to extract the most informative analytes, and overfitting the model was a substantial concern. Five analytes presented a reasonable tradeoff between model complexity and ability to describe the virtual population. We present the results for the adjusted R2 for linear models constructed for each VPop as a function of model size in Additional file 3.
Results and discussion
Calibration of the ensemble of virtual populations
The MAPEL algorithm links VP mechanistic axes to population-level statistics reported in clinical trials (Figure 2). When calibrating the clinical response of the VPops, we elected to focus on ACR results due to the wealth of data available from clinical trials in patients that do not respond well to methotrexate and the continued interest in this population for the development of new therapies. The unweighted cohort VPs exhibited a full spectrum of simulated ACR-N responses to all of the simulated interventions (available in Additional file 2), from no improvement (0%) to marked improvement (87%) for all tested therapies. Slightly larger ranges were covered with some of the interventions (21% worsening to 100% improvement), but remained within the feasible range in Additional file 1.
Mechanistic alterations in pathophysiology govern the response to rituximab
To more completely investigate the mechanistic contrasts between VPops that responded well to rituximab from those that responded poorly, we grouped VPops with larger mean responses (ACR-N > 48, thin line in Figure 4) and compared them to VPops with smaller mean responses (ACR-N < 44.75, heavy line in Figure 4). The cutoff of 44.75 was chosen since this was the mean response calculated from in the rituximab trial . Rather than directly contrast populations above and below the mean, we noticed a sizable number of alternate VPops with a mean ACR-N score greater than 48. These VPops appeared to incorporate substantial mechanistic heterogeneity (Figure 6A, populations at right). To contrast these VPops, boxplots illustrating the median and interquartile range of the axes coefficients for these groups were constructed (Figure 6B). The axes were sorted by decreasing differences in the median upper axis bin weight. The axes in Figure 6B are ordered vertically, with decreasing separation between the VPops with strong and weaker responses. The axes near the top of the list exhibit the most separation between VPops that exhibit strong improvements with rituximab and those that do not. Interestingly, IFNβ production was the leading mechanistic axis identified, with lower IFNβ production associated with better response to rituximab.
Figure 6B is in agreement with published reports suggesting that a low type I interferon signature at baseline predicts responsiveness to rituximab . Although the authors speculated that the reasons could be a less B cell-dependent phenotype, they also suggest this explanation seems unlikely since all patients in their study were rheumatoid factor positive and/or anti-citrullinated peptide antibody positive. Furthermore, the non-response to rituximab appears to be associated with the persistence of B cells [33, 34]. We included alterations in B cell pathology in our axes and therefore sought to contrast the role the axes played in the response to rituximab. We “flipped” each mechanistic axis value for VPs weighted heavily in the population that responded well to values representative of populations that responded poorly to RTX (Additional file 4). The analysis confirmed a quantitatively important mechanistic effect for IFNβ production in the response to RTX. Interestingly, the axis flip analysis predicted that FLS parameters, more than directly modulating B cell growth, recruitment, or apoptosis, play a role in the inflammatory response to a therapeutic that depletes the B-cell population. The result is consistent with the view that that patient-to-patient variation in FLS biology may influence response to rituximab. The result is also consistent with the observation that the transplant of IFNβ competent FLS suppress inflammation in a collagen-induced arthritis model in IFNβ deficient mice .
IFNβ effect sensitivity analysis
Other mechanistic axes that appear to also be prognostic of the response to rituximab include prostaglandin E2 (PGE2), TNF, and IL-6 production (Figure 6B). PGE2 is a pleiotropic cytokine with both pro- and anti- inflammatory effects. For example, PGE2 inhibits the production of the potent pro-inflammatory cytokine TNF by macrophages [43-45]. By contrast, PGE2 can also potentiate pro-inflammatory Th17 T cell responses through IL-23 [46, 47]. It would be of interest to note whether there is an association between NSAID (non-steroidal anti-inflammatory drug) use and response to rituximab and, perhaps more importantly, whether NSAIDs may enhance the response to rituximab. Combining NSAIDs with rituximab in our simulations resulted in variable changes in ACR-N responses (−6% to 12%) in the VPops compared to rituximab alone (Additional file 5), in agreement with the general ineffectiveness of NSAIDs in RA. However, there were some VPs that did receive a marked benefit from the combination (weightings not shown), suggesting that targeting a subpopulation of such patients may be a future therapeutic direction. TNF and IL-6 are well established and validated clinical targets for RA for which approved biologic therapies are available. OC/OB activity and MMP-1 also appear to be good markers, suggesting that feedback from the bone and cartilage compartments may provide a mechanism to influence response to rituximab.
Formulation and analysis of multianalyte biomarkers predictive of the response to rituximab
Summary of advantages of MAPEL
There are a number of advantages to using MAPEL in order to develop VPops. First, all VPs are utilized to develop each VPop. Since all VPs are defined by the mechanistic axes, even those that ultimately receive low weights inform the analysis. For example, VPs with low weights may impact the axes weights if, during the convergence process, attempting to increase their weight decreases the composite goodness-of-fit. Second, the method allows the rapid generation of alternate VPops that are consistent with clinical data to enable population-level hypothesis generation while considering the goodness-of-fit. Third, the method is scalable to include many VPs. Because the weights are calculated from the axes, rather than the VPs, a large number of diverse VPs can be included. For example, we included 1,206 VPs when generating 768 alternate VPops. In the study discussed previously, 1 VPop was created with 145 VPs . A large degree of mechanistic variability can be introduced into the VPs to facilitate exploratory analyses of the effects of mechanistic variability. We varied 51 mechanistic axes, compared with, for example, six or eleven parameters in a model of DILI [15, 16].
Additional applications of MAPEL
Although we focus on the application of MAPEL to biosimulation results, there are additional potential applications that may find utility for researchers engaged in other systems biology and bioinformatics research. In theory, MAPEL can be applied with any high-dimensional dataset matched with clinical outcomes to extrapolate prevalence in a larger population. For example, plasma metabolite concentrations, tissue cytokine levels, proteomic measures, or other high-throughput data sources could be implemented as the mechanistic axes. Methods such as principal component analysis (PCA) or functional groupings could serve to condense the effective dimensionality of the axes if the dimensionality becomes intractable. Although the approach would require sample-matched results from multiple interventions in the small dataset, MAPEL would then essentially serve as an advanced regression technique that could be used to propose mechanistic prevalences in populations from larger trials. Furthermore, although we have employed the Entelos RA PhysioLab® platform, other mechanistic modeling approaches can be utilized with MAPEL to develop phenotype-informed weights for model solutions.
The MAPEL algorithm integrates mechanistic biosimulation results with clinical trial statistics to enable statistically-validated analyses of biomarkers and mechanistic determinants of disease progression at the population level. Applying weights directly to the axes, rather than to individual VPs, is a novel approach with several advantages. First, the algorithm executes with reasonable computational speed (less than 10 minutes per population on a Core 2 Duo processor for the cases explored here). In contrast to developing independent weights for individual virtual patients, the number of parameters is reduced and large cohorts of thousands of virtual patients become tractable for analysis. Second, the axes themselves describe biologically relevant mechanisms that yield insights into treatment response consistent with the literature for known therapeutics. The mechanistic axes complement synovial outputs to give a more complete understanding of the pathophysiology. Finally, integration with a mechanistic biosimulation platform facilitates testing at the population level to better segregate mechanistic factors from those merely arising from association. The MAPEL algorithm is a significant advance towards in the development of tools to enable a systems-level understanding of complicated diseases, such as RA.
We illustrate how these methods can be applied to interpret the type I interferon signature that has been observed to vary with patient responses to rituximab. Together, our results suggest two distinct mechanisms may play a role in establishing the poor response to rituximab. First, type I interferons such as IFNβ may play some role to reduce inflammation in RA. In patients with an underlying pathophysiology that is less driven by B cells and FLS, type I interferon reduction by rituximab may counteract some of the therapeutic effect. Second, in patients with pathophysiologies where B cells play a quantitatively more substantial role, the suppressive effects of the type I interferons are still present but play a smaller role. The pathology is substantially altered to facilitate a clinically adequate response.
The authors would like to acknowledge the following people: Leif Wennerberg for discussion of statistical approaches during algorithm development; and Lyn Powell, Michael Morimoto, Robert Paine, and Karim Wahba for thoughtful review of the manuscript.
- Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.View ArticlePubMedGoogle Scholar
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & rheum. 2010, 62: 2569-81. 10.1002/art.27584.View ArticleGoogle Scholar
- McInnes IB, Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007, 7: 429-442. 10.1038/nri2094.View ArticlePubMedGoogle Scholar
- Felson D, Anderson J, Boers M: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis & rheum. 1993, 36: 729-740. 10.1002/art.1780360601.View ArticleGoogle Scholar
- Anderson JJ, Wells G, Verhoeven AC, Felson DT: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis & rheum. 2000, 43: 22-29. 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9.View ArticleGoogle Scholar
- Lipsky PE, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J, Smolen J, Weisman M, Emery P, Feldmann M, Harriman G, Maini R: Infliximab and methotrexate in the treatment of rheumatoid arthritis. NEJM. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.View ArticlePubMedGoogle Scholar
- Brennan FM, Mcinnes IB: Evidence that cytokines play a role in rheumatoid arthritis. Cytokine. 2008, 118: 3537-3545.Google Scholar
- Pammolli F, Magazzini L, Riccaboni M: The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discovery. 2011, 10: 428-438. 10.1038/nrd3405.View ArticleGoogle Scholar
- Demin I, Hamrén B, Luttringer O, Pillai G, Jung T: Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. J Clin Pharm Ther. 2012, 92: 352-359. 10.1038/clpt.2012.69.View ArticleGoogle Scholar
- Schmidt BJ, Papin JA, Musante CJ: Mechanistic systems modeling to guide drug discovery and development. Drug Discov Today. 2013, 18: 116-127. 10.1016/j.drudis.2012.09.003.PubMed CentralView ArticlePubMedGoogle Scholar
- Sheiner L, Wakefield J: Population modelling in drug development. Stat Methods Med Res. 1999, 8: 183-193. 10.1191/096228099672920676.View ArticlePubMedGoogle Scholar
- Powell LM, Lo A, Cole MS, Trimmer J: Application of Predictive Biosimulation to the Study of Atherosclerosis: Development of the Cardiovascular PhysioLab Platform and Evaluation of CETP Inhibitor Therapy. 2007, Stuttgart, Germany: Proceedings of the FOSBE, 295-302.Google Scholar
- Kansal AR, Trimmer J: Application of predictive biosimulation within pharmaceutical clinical development : examples of significance for translational medicine and clinical trial design. IEE Proc-Syst Biol. 2005, 152: 214-220. 10.1049/ip-syb:20050043.View ArticleGoogle Scholar
- Klinke DJ: Integrating epidemiological data into a mechanistic model of type 2 diabetes: validating the prevalence of virtual patients. Ann Biomed Eng. 2008, 36: 321-334. 10.1007/s10439-007-9410-y.View ArticlePubMedGoogle Scholar
- Woodhead JL, Howell BA, Yang Y, Harrill AH, Clewell HJ, Andersen ME, Siler SQ, Watkins PB: An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. JPET. 2012, 342: 529-540. 10.1124/jpet.112.192930.View ArticleGoogle Scholar
- Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ, Andersen ME, Siler SQ, Watkins PB: In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsymTM: a mechanistic, mathematical model of DILI. J Pharmacokinet Phar. 2012, 39: 527-541. 10.1007/s10928-012-9266-0.View ArticleGoogle Scholar
- Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH: Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis & rheum. 2011, 63: 1265-1273. 10.1002/art.30273.View ArticleGoogle Scholar
- Rullman J, Struemper H, Defranoux N, Ramanujan S, Meeuwisse C, van Elsan A: Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. IEE Proc-Syst Biol. 2005, 152: 256-262. 10.1049/ip-syb:20050053.View ArticleGoogle Scholar
- Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP: Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis & rheum. 2010, 62: 3607-3614. 10.1002/art.27702.View ArticleGoogle Scholar
- Shoda L, Kreuwel H, Gadkar K, Zheng Y, Whiting C, Atkinson M, Bluestone J, Mathias D, Young D, Ramanujan S: The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin & Exp Imm. 2010, 161: 250-267.Google Scholar
- Ihaka R: R : A language for data analysis and graphics. J Comput Graph Stat. 1996, 5: 299-314.Google Scholar
- Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEJM. 2004, 350: 2572-2581. 10.1056/NEJMoa032534.View ArticlePubMedGoogle Scholar
- Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland A-M, Vernon E, Ambs P, Fleischmann R: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis & rheum. 2011, 63: 609-621. 10.1002/art.30158.View ArticleGoogle Scholar
- Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008, 371: 987-997. 10.1016/S0140-6736(08)60453-5.View ArticlePubMedGoogle Scholar
- Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis & rheum. 2004, 50: 1400-11. 10.1002/art.20217.View ArticleGoogle Scholar
- Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker J-C, Lin C, Cornet PLN, Dougados M: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008, 67: 1096-1103. 10.1136/ard.2007.080002.PubMed CentralView ArticlePubMedGoogle Scholar
- Klaassen CAJ, Wellner JA, Mar N: Efficient estimation in the bivariate normal copula model: normal margins are least favourable. Bernoulli. 1997, 3: 55-77. 10.2307/3318652.View ArticleGoogle Scholar
- Package “LEAPS”: Regression subset selection. http://cran.r-project.org/web/packages/leaps,
- Emery P, Deodhar A, Rigby W, Isaacs J, Combe B, Racewicz A, Latinis K, Abud-Mendoza C, Szczepanski L, Roschmann R, Chen A, Armstrong G, Douglass W, Tyrrell H: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2010, 69: 1629-1635. 10.1136/ard.2009.119933.PubMed CentralView ArticlePubMedGoogle Scholar
- Alvaro-Gracia J, Zvaifler N, Firestein G: Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest. 1990, 86: 1790-1798. 10.1172/JCI114908.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakajima H, Hiyama Y, Tsukada W, Warabi H, Uchida S, Hirose S: Effects of interferon gamma on cultured synovial cells from patients with rheumatoid arthritis: inhibition of cell growth, prostaglandin E2, and collagenase release. Ann Rheum Dis. 1990, 49: 512-516. 10.1136/ard.49.7.512.PubMed CentralView ArticlePubMedGoogle Scholar
- Brinckerhoff C, Guyre P: Increased proliferation of human synovial fibroblasts treated with recombinant immune interferon. J Immunol. 1985, 134: 42-46.Google Scholar
- Thurlings R, Vos K, Wijbrandts C, Zwinderman A, Gerlag D, Tak P: Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008, 67: 917-925.PubMed CentralView ArticlePubMedGoogle Scholar
- Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P: Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis & rheum. 2008, 58: 2993-2999. 10.1002/art.23902.View ArticleGoogle Scholar
- Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S: Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis & rheum. 2005, 52: 3739-3748. 10.1002/art.21496.View ArticleGoogle Scholar
- Porrini A, Gambi D, Reder A: Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995, 61: 27-34. 10.1016/0165-5728(95)00070-I.View ArticlePubMedGoogle Scholar
- Wang X, Chen M, Wandinger K, Williams G, Dhib-Jalbut S: IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol. 2000, 165: 548-557.View ArticlePubMedGoogle Scholar
- Rudick R, Ransohoff R, Peppler R, VanderBrug M, Lehmann P, Alam J: Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996, 40: 618-627. 10.1002/ana.410400412.View ArticlePubMedGoogle Scholar
- Duncan MR, Berman B: Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med. 1985, 162: 516-527. 10.1084/jem.162.2.516.View ArticlePubMedGoogle Scholar
- Vilcek J, Kohase M, Henrikson-DeStefano D: Mitogenic effect of double-stranded RNA in human fibroblasts: role of autogenous interferon. J Cell Physiol. 1987, 130: 37-43. 10.1002/jcp.1041300107.View ArticlePubMedGoogle Scholar
- Kohase M, Henrikson-DeStefano D, May LT, Vilcek J, Sehgal PB: Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell. 1986, 6: 659-666.View ArticleGoogle Scholar
- Vosslamber S, Raterman HG, van der Pouw Kraan TCTM, Schreurs MWJ, von Blomberg BME, Nurmohamed MT, Lems WF, Dijkmans BAC, Voskuyl AE, Verweij CL: Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis. 2011, 70: 1153-1159. 10.1136/ard.2010.147199.View ArticlePubMedGoogle Scholar
- Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T: Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med. 1994, 180: 2365-2370. 10.1084/jem.180.6.2365.View ArticlePubMedGoogle Scholar
- Niho Y, Niiro H, Tanaka Y, Nakashima H, Otsuka T: Role of IL-10 in the crossregulation of prostaglandins and cytokines in monocytes. Acta Haematol. 1998, 99: 165-170. 10.1159/000040831.View ArticlePubMedGoogle Scholar
- Fadok VA, McDonald P, Bratton DL, Henson PM: Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. Biochem Soc Trans. 1998, 26: 653-656.View ArticlePubMedGoogle Scholar
- Sheibanie A, Khayrullina T, Safadi F, Ganea D: Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis & rheum. 2007, 56: 2608-2619. 10.1002/art.22794.View ArticleGoogle Scholar
- Sheibanie A, Tadmori I, Jing H, Vassiliou E, Ganea D: Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 2004, 18: 1318-1320.PubMedGoogle Scholar
- Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K: Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Imm. 2005, 25: 189-201. 10.1007/s10875-005-4091-5.View ArticleGoogle Scholar
- Pers J-O, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci. 2005, 1050: 34-39. 10.1196/annals.1313.004.View ArticlePubMedGoogle Scholar
- Zhang M, Ko K-H, Lam QLK, Lo CKC, Srivastava G, Zheng B, Lau Y-L, Lu L: Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol. 2005, 17: 1081-1092. 10.1093/intimm/dxh287.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.